Watch this enlightening conversation focused on the transforming power of antibody-drug conjugates (ADCs) like T-DXd (trastuzumab deruxtecan) in HER2-positive breast cancer therapy with Dr. Anne O’Dea and Dr. VK Gadi. The doctors provide hope for T-DXd’s potential usage as a first-line treatment, which could change present guidelines away from conventional chemotherapy treatments like the Cleopatra regimen, notable for their high toxicity. Effective, focused therapy with less side effects provided by T-DXd could improve patients’ quality of life and maybe increase general survival.They also discuss the value of HER2 testing, pointing out that patients labeled as HER2-low or ultra-low could still benefit from T-DXd , therefore stressing the need of more exact diagnostic criteria. Trials like DB12 and DESTINY-Breast06 under progress allow Dr. O’Dea and Dr. Gadi optimism for improved understanding of ideal therapy sequencing, particularly for managing brain metastases—a major difficulty in HER2-positive cases.Emphasizing personalizing, strategic sequencing, and future research to generate better outcomes and, finally, the possibility for more curative medicines, their discussion shows an emerging approach to HER2 treatment.🎧 Don’t forget to like, share, and subscribe for more CHM Conversations#BreastCancer #OncologyPodcast #TDXd #HER2Low #CHMConversations #PrecisionMedicine #CancerResearch–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Join Dr. VK Gadi and Dr. Jason Mouabbi at a recent conference for their discussion around the changing function of antibody-drug conjugates (ADCs) such as T-DXd (trastuzumab deruxtecan) in treating HER2-positive breast cancer, especially in patients with central nervous system (CNS) metastases. The talk hinges on the historical use of tiny compounds like tucatinib to ensure they’re able to pass the blood-brain barrier. New research, however, challenges the conventional wisdom on treatment restrictions by showing that ADCs might also be useful in this environment.

Dr. Mouabbi offered a real-world illustration of T-DXd’s transforming power by sharing a clinical case whereby it produced amazing regression of both visceral and central nervous system disorders. Data from studies like as DESTINY-Breast04 and the forthcoming DB12 study, which concentrates on patients with untreated or stable brain metastases, could provide vital direction on T-DXd’s efficacy in CNS care. In line with the encouraging findings observed in clinical practice, this trial seeks to confirm T-DXd’s influence on brain metastases.

The discussion also touches on the need for closely monitoring patients, especially for possible side effects including interstitial lung disease (ILD), with doctors using routine CT imaging and pulmonary function testing. Dr. Mouabbi underlined that novel treatments such as T-DXd represent a turning point in the field and give patients with metastatic breast cancer hitherto unheard-of hope.

You can watch the full conversation between Dr. Gadi and Dr. Mouabbi below to hear more of their experience and analysis of how ADCs are changing HER2-positive breast cancer treatment, therefore offering patients with advanced illness more focused and efficient choices.

🎧 Don’t forget to like, share, and subscribe for more CHM Conversations

#BreastCancer #OncologyPodcast #TDXd #HER2Low #CHMConversations #PrecisionMedicine #CancerResearch

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

What happens when MD Anderson’s translational firebrand Jason Mouabbi sticks a microphone in front of long-time HER2 guru Mothaffar Rimawi just days after the first read-out of DESTINY-Breast09? In sixty candid minutes they chart how trastuzumab deruxtecan (T-DXd) ± pertuzumab vaulted past CLEOPATRA; posting a headline 41-month PFS that forces oncologists to rethink induction/maintenance dogma, sequencing, and even the forbidden word “cure.” in what was previously considered uncurable. Along the way they debate ILD fears, whether any patient should ever leave the clinic without concurrent endocrine therapy, and christen T-DXd as “the great equalizer” for tumors burdened by ESR1, PIK3CA or BRCA mutations. By the end, Dr. Rimawi’s motto “put your best player in at kickoff” feels less like a bravado and more like the tomorrow’s standard of care.

Why you’ll want to listen

• Design matters: how DB-09’s two experimental arms (T-DXd alone vs T-DXd + pertuzumab) were built to settle the dual-blockade question once and for all.

• A 41-month shockwave: the largest PFS ever seen in metastatic HER2-positive breast cancer—and why it may still climb.

• Induction vs “until further notice”: can oncologists still offer a chemo-free maintenance phase, or does the ADC stay on forever?

• ILD in real life: 12 % remains, but community doctors already trade scheduled breaks for lower risk without sacrificing depth of response.

• Sequencing after an early ADC: if T-DXd moves up front, what’s left for tucatinib, T-DM1 or neratinib and more importnatly does it matter?

• Cure? Dare we say it: Rimawi argues we are “closest in any solid tumor” to normal life expectancy; Dr. Mouabbi pushes him to define what bold looks like.

• Endocrine cross-talk—still ignored: fewer than 10 % of DB-09 patients got concomitant endocrine therapy despite 60 % ER-positivity, a missed chance the speakers vow to fix.

• PI3K mutation? Payload doesn’t care: why the ADC’s topoisomerase warhead levels the playing field across resistance genotypes.

🎧 Like, share, and subscribe for more CHM Conversations that turn headline data into bedside decisions.

#BreastCancer #HER2Positive #TDXd #DESTINYBreast09 #OncologyPodcast #PrecisionMedicine #CHMConversations

–

Thanks for listening!

Our podcasts are also available on:

• Youtube - youtube.com/@CommunityHealthMedia

• Amazon Music - amazn.so/chm-podcast

• Apple Podcast - podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - castbox.fm/vh/6735434

• Goodpods - goodpods.com/profile/chm-111066

• iHeartRadio - iheart.com/podcast/291542082

• Pocket Casts - pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media